Today’s AI Top Pick: ALNY

8/12/2026 · Recently Alerted GARP screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Recently Alerted GARPALNYBUY NOW8.8 / 108/12/2026

Alnylam is the cleanest confluence of blockbuster fundamentals and an oversold, high-slope forecast tape. The screen fundamentals are elite: PEG 0.29, salesYoY 95.14%, epsNextY 48.82%, ROE 100.7%, profit margin 16.82%, gross margin 79.65%, recom 1.6, targetUpsidePct 71.4%. This is not a marginal GARP name — it's a hypergrowth biotech that also happens to clear the value screen. Few candidates in this pool combine growth of that magnitude with a PEG under 0.3. The forecast tape is exceptional and low-risk on entry. On the 4h, fc_short/mid/long print 46.57 / 67.38 / 73.31 with position_in_21bar_range at just 4.42% and drawdown -33.18% — the definition of oversold with strong forward slope. The 1d agrees: 34.89 / 62.74 / 57.32 with pos_in_range 18.79%. Near_term_bullish is 1.0 and bullish_prob 1.0. Unlike CALX (100% pos, chasing) or INTU (94% pos, near_term only 0.2), ALNY is not extended — you are buying into a washout with a forecast that projects a ~30–60% mean reversion. The weekly tape (fc -9.8 / -4.0 / -3.2) is the one blemish and it's why this is a swing setup rather than a multi-quarter hold — the higher-timeframe trend needs repair. However, the 4h/1d dominate near-term entry timing, and the weekly is not deteriorating from a top but rather absorbing the -30.34% 21-bar drop already priced in. News check is the tiebreaker. The 'Drugs that missed the mark' headline is a generic industry roundup, not a specific ALNY guidance cut or trial failure, and the 'implied volatility surging' note actually supports the forecast: options market is pricing in a large move consistent with the setup. Contrast this with APP (BofA downgrade), OPFI (multiple PT cuts on weak Q2), FUTU (DOJ probe), ONON (Q2 miss and guide down, -17.8%), MNDY (Wolfe downgrade), SRAD (2026 outlook cut), FOUR (Iran turmoil) — those are landmines that undercut otherwise-strong forecasts. ALNY has the strongest signal-to-noise ratio in the pool today.

Entry zone

$215–$225 (scale in around current $221.06; add on any dip toward the 4h VWAP anchor near $215)

Stop loss

$198 (below the 1d 21-bar low / -10% risk; a break here invalidates the mean-reversion thesis)

First target

$260 (roughly the 4h fc_short +17% / -25% recovery from drawdown high)

Longer target

$320–$340 (aligns with 4h fc_long +73% zone and consensus 71.4% upside; multi-month swing)

Risks

Weekly forecast is negative across all horizons (-9.8 / -4.0 / -3.2%) — higher-timeframe trend is not yet repaired, meaning any macro/biotech risk-off can reassert the downtrend from -49.15% perfYear.
Elevated implied volatility (per Aug 6 headline) suggests a catalyst event pending; a data readout or guidance surprise could produce a >15% single-day gap either direction.
Debt/Equity 2.21 and fwdPe 21.99 leave little cushion if EPS growth misses the 48.82% expectation, especially with rate-sensitive biotech multiples.
The 'drugs that missed the mark' industry article is vague — if a specific ALNY pipeline setback surfaces, the -33% drawdown could deepen to $180 quickly.
Institutional ownership at 98.99% means limited marginal buyer; any fund derisking can create outsized selling pressure.

Honorable mentions

BILICleanest multi-timeframe alignment in the pool — 4h fc 31.68/47.32/53.64, 1d 24.64/42.84/36.15, near_term_bullish 1.0, positive 'undervalued' headline, PEG 0.52, and pos_in_range 28–37% (not chasing). Safer than ALNY with less catalyst risk but lower magnitude.

WMGCleanest news (Q3 beat, 'high-quality compounder at better price'), near_term_bullish 0.8, ROE 92.17, PEG 0.31, and forecasts positive across all four timeframes on 1d/1wk. Modest forecast magnitudes (fc_long 14.81% on 1d) cap upside vs. ALNY but the setup is the most durable.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	ALNY	BUY NOW	8.8	Elite fundamentals (PEG 0.29, salesYoY 95%) plus 4h fc 46/67/73 at pos 4.42% — oversold hypergrowth setup.
2	BILI	BUY NOW	8.1	MTF-aligned bullish forecasts, positive 'undervalued' news, mid-range entry at pos 28-37%.
3	WMG	BUY NOW	7.5	Q3 beat and 'high-quality compounder' narrative with PEG 0.31 and positive fc on all TFs.
4	PODD	BUY PULLBACK	7.2	Monster 4h fc 70/74/94 but pos 12.98% and post-earnings PT cuts create chop risk.
5	BIRK	BUY NOW	7.0	All four TFs positive with modest slopes; near_term 0.8 and clean fundamentals PEG 0.83.
6	HUBS	BUY PULLBACK	6.8	Director insider buy after 52% drop, 1d fc_long 74.99% and 1wk 102.95% — but customer-growth guide cut headline.
7	INTR	BUY PULLBACK	6.6	PEG 0.22, fwdPe 5.26, 4h fc 56/65/72, positive 'record Q2' framing but pos_in_range 0% on 1wk.
8	FICO	BUY PULLBACK	6.5	4h fc 33/25/36 and Barclays overweight held, but pos 0.83% on 1d after -38.59% YTD — knife-catch.
9	NRG	BUY PULLBACK	6.2	Near_term_bullish 1.0 and 1d fc 8/28/20, but weekly fc -4.75/-29/-28.83 warns of trend break.
10	MLCO	BUY PULLBACK	6.0	Clean 'worst is behind us' narrative, PEG 0.36, 1wk fc 2.46/32.4/44 — but pos 100% on 4h is stretched.
11	FOUR	WAIT	5.8	4h fc 44/48/34 is compelling but Iran turmoil headline is a fresh landmine.
12	VERX	BUY PULLBACK	5.7	1d fc_long 64.21% and 'stock still looks cheap after 56% drop' but PE 568 and profit margin 0.45%.
13	INTU	WAIT	5.6	1d fc_long 80.69% but near_term_bullish 0.2 and pos 94.4% on 1d — extended near-term.
14	MIR	WAIT	5.4	4h fc 38/30/44 but 1wk fc negative and PE 173 — quality is thin.
15	CALX	BUY PULLBACK	5.3	Fundamentals check out but pos 100% on 4h and 97% on 1d — do not chase.
16	AAON	WAIT	5.1	Raised 2026 guide but shares fell 10.2% and 1wk fc negative -4/-10/-8.
17	PFSI	WAIT	5.0	4h fc 29/42/63 but PT cut 13.64% and 'risky value' framing on multiple analyst notes.
18	KVYO	WAIT	4.8	Solid top-line but 'reduced gross margin outlook' post-Q2 and pos 95.94% on 4h.
19	PDD	WAIT	4.7	PE 9.86 and PEG 0.66 are attractive but 'regulatory risk makes discount deserved' headline caps upside.
20	ORCL	WAIT	4.6	1d fc 0/17/31 but 4h/1wk mostly negative and layoff rumors overhang.
21	SRAD	AVOID	4.5	UBS downgrade and 'cut 2026 outlook' after Q2 loss — broken narrative.
22	CRK	WAIT	4.4	1d pos 100% with 1wk fc negative -7/-7/-5; shortFloat 31.71% is a squeeze/rug two-way risk.
23	ONON	WAIT	4.2	Fresh -17.8% drop on mixed Q2 with lower-end guidance — bull case needs to reset.
24	FUTU	AVOID	4.0	DOJ probe and class actions in the US override the strong 4h forecast.
25	MNDY	WAIT	3.9	Wolfe downgrade to Peer Perform and near_term_bullish 0.2 despite Q2 beat.
26	QTWO	WAIT	3.7	RSI 70.15, pos 93.49% on 1wk, and near-flat mid-horizon fc — extended and low upside.
27	APP	AVOID	3.5	BofA downgrade plus 'growth target harder to defend' plus 1wk fc -13.9/-36.1/-43.9 — trend break.
28	OPFI	AVOID	3.3	Multiple analysts cut forecasts on weak Q2 — 4h forecast strength is not enough against fundamental damage.
29	CCC	AVOID	3.0	RSI 71.67 and pos 87-95% with negative 4h fc -7.5/-6.1/-2.7 — near top with weakening forecast.
30	FRSH	AVOID	2.6	All-horizon negative forecasts (4h -15.7/-26.8/-17.6, 1wk -18.6/-15.5) and bullish_prob 0 — screen is a mirage.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord